MedTrace Logo

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

NCT07261631 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Conditions

Interventions

DRUG

68Ga-NNS309

Diagnostic investigational radiopharmaceutical

DRUG

177Lu-DFC413

Therapeutic investigational radiopharmaceutical

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2029-05-09
Completion
2029-05-09
FDA Drug
Yes

Countries

  • Canada
  • Denmark
  • France
  • Germany
  • Israel
  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07261631 on ClinicalTrials.gov